Top

Published in:

01-08-2009 | Original Article

Use of a single [¹²³I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease

Authors: Ruth Djaldetti, Therese A. Treves, Ilan Ziv, Eldad Melamed, Yair Lampl, Mordechai Lorberboym

Published in: Neurological Sciences | Issue 4/2009

Abstract

The aim of this study was to assess the ability of a single SPECT performed in the early stage of Parkinson’s disease (PD) to predict disease severity in 19 patients with early PD. [¹²³I]-FP-CIT striatal uptake was expressed as a ratio of specific:nonspecific uptake for defined brain areas. Clinical severity was determined by the UPDRS at baseline and 12–15 months following the SPECT procedure. [¹²³I]-FP-CIT uptake in the contralateral putamen and striatum was correlated with UPDRS score at baseline, with a more significant correlation after 1-year interval. [¹²³I]-FP-CIT uptake in all areas was correlated with bradykinesia and rigidity subscores only at follow up visit. Significant correlations were found between [¹²³I]-FP-CIT uptake in the contralateral striatum, putamen and caudate and the difference between motor scores of 1-year interval (ΔUPDRS). These results suggest that disease severity might be anticipated by a single SPECT at an early stage of the disease.

Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B et al (1996) [¹²³I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237PubMed

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG et al (1997) [¹²³I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140PubMedCrossRef

Mozley PD, Schneider JS, Acton PD, Plossl K, Stern MB, Siderowf A et al (2000) Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 41:584–589PubMed

Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:294–298PubMedCrossRef

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef

Marshall V, Grosset DG (2003) Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 18(Suppl 7):S22–S27PubMedCrossRef

Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP (1999) ¹²³I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology 52:1422–1426PubMed

Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y (2004) ¹²³I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45:1688–1693PubMed

Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [¹²³I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 21:510–514PubMedCrossRef

10.

Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol 115:1–17

11.

Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L et al (2000) [¹²³I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158–1167PubMedCrossRef

12.

Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T et al (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303–312PubMedCrossRef

13.

Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson’s disease. Brain 119:2097–2103PubMedCrossRef

14.

Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y et al (1995) Decreased single-photon emission computed tomographic [¹²³I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38:589–598PubMedCrossRef

15.

Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH et al (1997) Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [¹²³I]IPT and single-photon emission tomography. Eur J Nucl Med 24:415–421PubMed

16.

Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with ¹²³I-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698PubMedCrossRef

17.

Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S et al (2001) [¹²³I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 57:2089–2094PubMed

18.

Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T (2003) Measuring the rate of progression of Parkinson’s disease over a 5-year period with beta-CIT SPECT. Mov Disord 18:1266–1272PubMedCrossRef

19.

Dujardin K, Defebvre L, Duhamel A, Lecouffe P, Rogelet P, Steinling M et al (2004) Cognitive and SPECT characteristics predict progression of Parkinson’s disease in newly diagnosed patients. J Neurol 251:1383–1392PubMedCrossRef

20.

Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO (2006) Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord 21:958–963PubMedCrossRef

21.

Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C et al (1997) Measurement of the dopaminergic degeneration in Parkinson’s disease with [¹²³I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9–24PubMed

22.

Spiegel J, Hellwig D, Samnick S, Jost W, Möllers MO, Fassbenger K et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335PubMedCrossRef

23.

Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P et al (2007) [¹²³I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor vs. akinetic-rigid onset. Neuroreport 18:1499–1502PubMedCrossRef

Title: Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease
Authors: Ruth Djaldetti
Therese A. Treves
Ilan Ziv
Eldad Melamed
Yair Lampl
Mordechai Lorberboym
Publication date: 01-08-2009
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 4/2009
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-009-0100-4

At a glance: The STEP trials

Springer Medicine

Use of a single [¹²³I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Late onset generalized myasthenia gravis presenting with facial weakness and bulbar signs without extraocular muscle involvement

Death in Unverricht–Lundborg disease

Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia

Medulla oblongata tuberculoma mimicking metastasis presenting with stroke-like symptoms

Interesting sign of Bell’s palsy in an ear wiggler

Transient parkinsonism in isolated extrapontine myelinolysis